HK134494A - Substituted release azelastine containing medicaments - Google Patents

Substituted release azelastine containing medicaments

Info

Publication number
HK134494A
HK134494A HK134494A HK134494A HK134494A HK 134494 A HK134494 A HK 134494A HK 134494 A HK134494 A HK 134494A HK 134494 A HK134494 A HK 134494A HK 134494 A HK134494 A HK 134494A
Authority
HK
Hong Kong
Prior art keywords
azelastine
release
containing medicaments
substituted
substituted release
Prior art date
Application number
HK134494A
Other languages
English (en)
Inventor
Helmut Dr Hettche
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of HK134494A publication Critical patent/HK134494A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Switches With Compound Operations (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Rotary Pumps (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK134494A 1988-04-20 1994-12-01 Substituted release azelastine containing medicaments HK134494A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3813244 1988-04-20

Publications (1)

Publication Number Publication Date
HK134494A true HK134494A (en) 1994-12-09

Family

ID=6352451

Family Applications (1)

Application Number Title Priority Date Filing Date
HK134494A HK134494A (en) 1988-04-20 1994-12-01 Substituted release azelastine containing medicaments

Country Status (15)

Country Link
EP (1) EP0338444B1 (fr)
JP (1) JP2950845B2 (fr)
AT (1) ATE97572T1 (fr)
AU (1) AU3318389A (fr)
CA (1) CA1325976C (fr)
DE (1) DE58906232D1 (fr)
DK (1) DK172235B1 (fr)
ES (1) ES2060685T3 (fr)
FI (1) FI891865A (fr)
HK (1) HK134494A (fr)
HU (1) HU202403B (fr)
IE (1) IE62778B1 (fr)
MC (1) MC2025A1 (fr)
PT (1) PT90308B (fr)
ZA (1) ZA892877B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9003903D0 (sv) * 1990-12-07 1990-12-07 Astra Ab New pharmaceutical formulations
DE4207234A1 (de) * 1992-03-07 1993-09-09 Asta Medica Ag Neue aminocarbonsaeure-derivate mit antiallergischer/antiasthmatischer wirkung und verfahren zu deren herstellung
JPH0710747A (ja) * 1993-04-28 1995-01-13 Takeda Chem Ind Ltd 固形製剤およびその製造方法
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
JP4138910B2 (ja) * 1997-07-02 2008-08-27 帝國製薬株式会社 経皮吸収性が良好で且つ皮膚刺激性の少ない塩酸アゼラスチン含有経皮製剤
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
CA2348871C (fr) 1998-11-02 2009-04-14 John G. Devane Composition a liberation modifiee multiparticulaire
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
MXPA02004293A (es) 1999-10-29 2002-10-31 Euro Celtique Sa Formulaciones de hidrocodona de liberacion controlada..
EP1337244A4 (fr) 2000-10-30 2006-01-11 Euro Celtique Sa Preparations d'hydrocodone a liberation lente
EP1396263A1 (fr) * 2002-08-09 2004-03-10 Warner-Lambert Company Compositions d'enrobage pour tablettes et caplets
CA2510319A1 (fr) * 2002-12-20 2004-07-15 Thomas J. Smith Compactage haute pression pour formulations pharmaceutiques
LT2486942T (lt) * 2004-11-24 2019-01-25 Meda Pharmaceuticals Inc. Kompozicijos, apimančios azelastiną ir jų panaudojimo būdai
CN110575445B (zh) 2013-03-21 2023-08-18 优普顺药物公司美国分部 可注射的持续释放组合物及其用于治疗关节炎症及相关疼痛的方法
ES2672993T3 (es) 2015-10-27 2018-06-19 Eupraxia Pharmaceuticals Inc. Formulaciones de liberación sostenida de anestésicos locales

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0174464B1 (fr) * 1984-09-14 1990-01-03 ASTA Pharma AG Benzyl-phtalazinones substitués

Also Published As

Publication number Publication date
ES2060685T3 (es) 1994-12-01
HU202403B (en) 1991-03-28
AU3318389A (en) 1989-10-26
HUT49808A (en) 1989-11-28
DK189189D0 (da) 1989-04-19
EP0338444B1 (fr) 1993-11-24
FI891865A0 (fi) 1989-04-19
DE58906232D1 (de) 1994-01-05
DK172235B1 (da) 1998-02-02
EP0338444A1 (fr) 1989-10-25
DK189189A (da) 1989-10-21
ZA892877B (en) 1989-12-27
ATE97572T1 (de) 1993-12-15
PT90308A (pt) 1989-11-10
JPH01311024A (ja) 1989-12-15
CA1325976C (fr) 1994-01-11
JP2950845B2 (ja) 1999-09-20
PT90308B (pt) 1994-10-31
FI891865A (fi) 1989-10-21
MC2025A1 (fr) 1990-04-25
IE891263L (en) 1989-10-20
IE62778B1 (en) 1995-02-22

Similar Documents

Publication Publication Date Title
IL95691A0 (en) Thienylcarboxylates of amino alcohols,their preparation and pharmaceutical compositions containing them
PT615754E (pt) Formas solidas de administracao oral de libertacao controlada flupertina
EP0427247A3 (en) Pharmaceutical composition with r-alpha-lipoic acid or s-alpha-lipoic acid as the active ingredient
GR3007202T3 (fr)
HK134494A (en) Substituted release azelastine containing medicaments
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
GR1003711B (el) Μεθοδος δια την παρασκευη φαρμακευτικων συνθεσεων δια συστηματικην διαδερμικην χορηγησιν.
IL85523A (en) Stable alpha interferon complex,its preparation and pharmaceutical compositions comprising it
SE8804629A (fr)
NZ218028A (en) Benzimidazole derivatives and pharmaceutical compositions
ZA876731B (en) Therapeutic agents
DE3766200D1 (de) L-dopa enthaltendes arzneimittel.
PT86186A (en) Process for the preparation of benzimidazol derivatives and of pharmaceutical compositions containing the same
GR3006091T3 (fr)
GR890100833A (en) Process for the preparation of a compound with gastric inhibitopy effect
DE3474774D1 (en) Therapeutic compositions for oral use containing stable s-adenosy1-l-methionine salts
HU895241D0 (en) Process for the preparation of substituted 1,3,5-triazin-trione derivatives and pharmaceutical compositions containing said compounds as active ingredient
GB2021409A (en) Pharmaceutical composition
GR3002765T3 (en) New pharmaceutical compositions for parenteral use containing a calcitonin as the active ingredient
HUT50787A (en) Process for producing pharmaceutical compositions comprising 4-aryl-4-piperidine-, pyrrolidine- or hexahydroazepincarbinol derivatives or heterocyclic analogs thereof as active ingredient and process for producing the new compounds
HU9700842D0 (en) Pharmaceutical compositions based on stabilized lipophyl matrix giving controlled release for the active components
EP0380989A3 (en) Plaster for transdermal administration
EP0351876A3 (fr) Composition pour augmenter l'effet de vaccination
HK1001822A1 (en) Medicinal form for oral application for the once-a-day treatment of hypertension by diltiazem hydrochloride
GR3031360T3 (en) Composition based on ibuprofen, for oral usage

Legal Events

Date Code Title Description
PF Patent in force
CHPA Change of a particular in the register (except of change of ownership)
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20080414